Opinion|Videos|June 21, 2024
Clinical Pearls for the Management of Patients Suffering from Narcolepsy
Karl Doghramji, MD, FAASM, DFAPA, and Chelsie Monroe, MSN, APN, PMHNP-BC, conclude the discussion with advice for clinicians who treat patients with narcolepsy.
Advertisement
Episodes in this series
Advertisement
Related to this article
Phase 2 trial shows daridorexant boosts pediatric insomnia sleep time up to 50 minutes, including ADHD/ASD patients, with strong safety and phase 3 plans.
Sleep disruption fuels Alzheimer risk via apnea, fragmentation, and inflammation; improving consolidated sleep, medication review, and sleep-specialist teamwork may protect cognition.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Assessing Interventions for Insomnia in Peri- and Postmenopausal Women
2
October 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
3
Food Noise and GLP-1 Drugs: What Research Reveals About Motivation and Appetitive Drive
4
ALKS 7290 for Adjunctive Treatment for MDD Enters Phase 2 Study
5